NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
NewcelX (NASDAQ: NCEL) announced on November 6, 2025 that Professor Tamir Ben-Hur, MD, PhD, will join its Scientific Advisory Board.
Prof. Ben-Hur is a professor of neurology at Hadassah and Hebrew University, described as an expert in neuroimmunology and stem-cell regenerative medicine. Management said his appointment brings clinical expertise to NewcelX's programs targeting ALS and diabetes. The company framed his commitment as an endorsement of the Merger that unites Kadimastem's stem-cell platforms with NLS Pharmaceutic's CNS therapeutics capabilities.
NewcelX (NASDAQ: NCEL) ha annunciato il 6 novembre 2025 che il Professor Tamir Ben-Hur, MD, PhD, entrerà a far parte del suo Consiglio consultivo scientifico.
Il Prof. Ben-Hur è professore di neurologia presso Hadassah e la Hebrew University, descritto come esperto in neuroimmunologia e medicina rigenerativa a base di cellule staminali. La direzione ha affermato che la sua nomina porterà competenze cliniche ai programmi di NewcelX che mirano a ELA (sclerosi laterale amiotrofica) e al diabete. L'azienda ha inquadrato il suo impegno come l'approvazione della fusione che unisce le piattaforme di cellule staminali di Kadimastem alle capacità terapeutiche del sistema nervoso centrale (CNS) di NLS Pharmaceutics.
NewcelX (NASDAQ: NCEL) anunció el 6 de noviembre de 2025 que el Profesor Tamir Ben-Hur, MD, PhD, se unirá a su Consejo Asesor Científico.
El Prof. Ben-Hur es profesor de neurología en Hadassah y en la Universidad Hebrea, descrito como experto en neuroinmunología y medicina regenerativa con células madre. La dirección dijo que su nombramiento aporta experiencia clínica a los programas de NewcelX dirigidos a ELA y diabetes. La empresa enmarcó su compromiso como una aprobación de la fusión que une las plataformas de células madre de Kadimastem con las capacidades de terapeutica del sistema nervioso central (CNS) de NLS Pharmaceutics.
NewcelX (NASDAQ: NCEL)은 2025년 11월 6일에 Tamir Ben-Hur 박사, MD, PhD가 회사의 과학 자문위원회에 합류할 것이라고 발표했다.
벤흐르 교수는 하다산 병원(Hadassah)과 히브리 대학교의 신경학 교수로, 신경면역학 및 줄기세포 재생의학의 전문가로 묘사된다. 경영진은 그의 임명이 ALS와 당뇨병를 겨냥한 뉴셀엑스의 프로그램에 임상적 전문지식을 제공한다고 말했다. 이 회사는 Kadimastem의 줄기세포 플랫폼과 NLS Pharmaceutics의 CNS 치료 능력을 하나로 묶는 합병을 지지하는 것으로 그의 헌신을 해석했다.
NewcelX (NASDAQ: NCEL) a annoncé le 6 novembre 2025 que le Prof. Tamir Ben-Hur, MD, PhD, rejoindra son Conseil scientifique consultatif.
Le Prof. Ben-Hur est professeur de neurologie à Hadassah et à l'Université hébraïque, décrit comme expert en neuroimmunologie et en médecine régénérative par cellules souches. La direction a déclaré que sa nomination apporte une expertise clinique aux programmes de NewcelX ciblant ELA et diabète. La société a présenté son engagement comme l'approbation de la fusion qui unit les plateformes de cellules souches de Kadimastem aux capacités thérapeutiques du système nerveux central (CNS) de NLS Pharmaceutics.
NewcelX (NASDAQ: NCEL) gab am 6. November 2025 bekannt, dass Professor Tamir Ben-Hur, MD, PhD, dem Scientific Advisory Board des Unternehmens beitreten wird.
Prof. Ben-Hur ist Neurologe an Hadassah und der Hebräischen Universität und wird als Experte in Neuroimmunologie und zellulärer regenerativer Medizin beschrieben. Das Management sagte, seine Berufung brächte klinische Expertise in die Programme von NewcelX, die sich auf ALS und Diabetes konzentrieren. Das Unternehmen rief seinen Einsatz als Bekenntnis zur Fusion hervor, die Kadimastems Plattformen für Stammzellen mit NLS Pharmaceutics' CNS-Therapeutika-Fähigkeiten vereint.
NewcelX (NASDAQ: NCEL) أعلنت في 6 نوفمبر 2025 أن البروفيسور تامير بن-حور، MD، PhD، سينضم إلى المجلس الاستشاري العلمي للشركة.
يُوصف البروفيسور بن-حور بأنه أستاذ أعصاب في هداسا والجامعة العبرية، وخبير في علم المناعة العصبية و الطب التجديدي القائم على الخلايا الجذعية. قالت الإدارة إن تعيينه يضيف خبرة سريرية لبرامج شركة NewcelX التي تستهدف مرضALS والسكري. صاغت الشركة التزامه كتأييد لـ الاندماج الذي يوحّد منصات Kadimastem للخلايا الجذعية مع قدرات العلاجات العصبية المركزية (CNS) لدى NLS Pharmaceutics.
- Adds globally recognized neuroimmunology expert to Scientific Advisory Board
- Public endorsement of the Merger linking Kadimastem and NLS Pharmaceutic
- Strengthens clinical expertise for ALS and diabetes therapeutic programs
- None.
Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of
Prof. Tamir Ben-Hur said, "It is an honor to join this scientific journey and NewcelX as a global biotech advancing regenerative and neuroscience-based therapies. I am excited to see scientific success, expecting that by combining cell therapy and central nervous system drug innovation, NewcelX will deliver meaningful therapeutic advances for patients worldwide."
Prof. Michel Revel, Chief Scientific Officer of NewcelX, added, "Prof. Ben-Hur's involvement with NewcelX brings deep clinical expertise and a shared commitment to advancing innovative cell therapies that address the root causes of neurodegenerative disease."
Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX, stated, "We are honored that Prof. Ben-Hur will join us in NewcelX. His decision reflects confidence in our science and our mission to build a global biotechnology company delivering breakthrough therapies for ALS and diabetes."
The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.
About NewCelX Ltd.
NewcelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The Company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as ALS and Type 1 Diabetes. NewcelX is headquartered in
Social Media: LinkedIn, Facebook, X
Forward-Looking Statements
This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses the anticipated contributions of Prof. Ben-Hur to NewcelX's Scientific Advisory Board, the expected impact of his expertise on the Company's research and development programs, and the potential advancement of NewcelX's combined cell therapy and CNS drug development platforms following the merger of Kadimastem and NLS Pharmaceutics and its ability to deliver meaningful therapeutic advances for patients worldwide. These forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays in developing or introducing new technologies, products, or applications; and competitive pressures that could reduce market share or pricing. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the
Investor & Media Contacts
Sarah Bazak, Investors relations
InvestorRelations@newcelx.com
www.newcelx.com
Logo: https://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg
View original content:SOURCE NewcelX Ltd.
FAQ
Who is joining NewcelX's Scientific Advisory Board as of November 6, 2025 (NCEL)?
What expertise does Prof. Tamir Ben-Hur bring to NewcelX (NCEL)?
How did NewcelX describe the impact of Prof. Ben-Hur joining on its programs (NCEL)?
Does Prof. Ben-Hur's appointment relate to NewcelX's Merger (NCEL)?
When was the appointment of Prof. Tamir Ben-Hur to NewcelX's SAB announced (NCEL)?
